Capital Increase: Funding reduced, price lowered
페니트리움바이오
187660
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2680
Risk-adjusted indicator based on 2680 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Operating Funds (Revised): 24,222,500,000 KRW
- • Operating Funds (Original): 32,425,000,000 KRW
- • New Share Issuance Price (Revised): 3,085 KRW per share
- • New Share Issuance Price (Original): 4,050 KRW per share
- • Share Allocation Ratio: 0.1551578144 shares per existing share
- • Over-subscription Ratio: 0.2 shares per allocated new share
AI Analysis Summary
Penetrium Bioscience Inc. has amended its paid-in capital increase plan. The revised plan reduces the target operating funds from 32.425 billion KRW to 24.2225 billion KRW, a decrease of 8.2025 billion KRW. Concurrently, the new share issuance price has been lowered from an estimated 4,050 KRW to a confirmed 3,085 KRW per common share. Existing shareholders will be allocated 0.1551578144 new shares per existing share, with an over-subscription option of 0.2 shares. The lower issuance price and reduced funding amount suggest a potentially less favorable market reception or revised capital needs, leading to a negative financial impact due to increased dilution per KRW raised.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.